Cargando…

Outcomes in COPD patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroids

Patients with COPD are frequently prescribed inhaled corticosteroids (ICS); however, it is unclear whether the treatment with ICS might modify responses to inhaled bronchodilators. Two 6-month, randomized, placebo-controlled, double-blind, double-dummy, parallel-group studies of tiotropium 18 μg onc...

Descripción completa

Detalles Bibliográficos
Autores principales: Hodder, Richard, Kesten, Steven, Menjoge, Shailendra, Viel, Klaus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3321723/
https://www.ncbi.nlm.nih.gov/pubmed/18044688
_version_ 1782228974317862912
author Hodder, Richard
Kesten, Steven
Menjoge, Shailendra
Viel, Klaus
author_facet Hodder, Richard
Kesten, Steven
Menjoge, Shailendra
Viel, Klaus
author_sort Hodder, Richard
collection PubMed
description Patients with COPD are frequently prescribed inhaled corticosteroids (ICS); however, it is unclear whether the treatment with ICS might modify responses to inhaled bronchodilators. Two 6-month, randomized, placebo-controlled, double-blind, double-dummy, parallel-group studies of tiotropium 18 μg once daily, compared with salmeterol, 50 μg bid, had been conducted in patients with moderate-to-severe COPD. Efficacy was assessed by spirometry, transition dyspnea index (TDI), St. George’s Respiratory Questionnaire (SGRQ), and exacerbations. Data from both studies were combined to form subgroups with regard to concurrent use of ICS. 796 patients receiving ICS were separately analyzed from 390 patients not receiving ICS. Mean age was 64 years, and pre-bronchodilator FEV(1) was 1.06 L (ICS group) and 1.13 L (non-ICS group). Both bronchodilators increased morning mean ± SE pre-dose FEV(1) compared with placebo (ICS groups: tiotropium 110 ± 20 mL, salmeterol 80 ± 20 mL; non-ICS groups: tiotropium 150 ± 30 mL, salmeterol 110 ± 30 mL; p > 0.05 for tiotropium vs salmeterol). Improvements in TDI and SGRQ and frequency of exacerbations also tended to be more profound for tiotropium. Treatment with tiotropium in patients with moderate-to-severe COPD was superior to salmeterol in lung function, irrespective of concurrent use of ICS.
format Online
Article
Text
id pubmed-3321723
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-33217232012-04-10 Outcomes in COPD patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroids Hodder, Richard Kesten, Steven Menjoge, Shailendra Viel, Klaus Int J Chron Obstruct Pulmon Dis Original Research Patients with COPD are frequently prescribed inhaled corticosteroids (ICS); however, it is unclear whether the treatment with ICS might modify responses to inhaled bronchodilators. Two 6-month, randomized, placebo-controlled, double-blind, double-dummy, parallel-group studies of tiotropium 18 μg once daily, compared with salmeterol, 50 μg bid, had been conducted in patients with moderate-to-severe COPD. Efficacy was assessed by spirometry, transition dyspnea index (TDI), St. George’s Respiratory Questionnaire (SGRQ), and exacerbations. Data from both studies were combined to form subgroups with regard to concurrent use of ICS. 796 patients receiving ICS were separately analyzed from 390 patients not receiving ICS. Mean age was 64 years, and pre-bronchodilator FEV(1) was 1.06 L (ICS group) and 1.13 L (non-ICS group). Both bronchodilators increased morning mean ± SE pre-dose FEV(1) compared with placebo (ICS groups: tiotropium 110 ± 20 mL, salmeterol 80 ± 20 mL; non-ICS groups: tiotropium 150 ± 30 mL, salmeterol 110 ± 30 mL; p > 0.05 for tiotropium vs salmeterol). Improvements in TDI and SGRQ and frequency of exacerbations also tended to be more profound for tiotropium. Treatment with tiotropium in patients with moderate-to-severe COPD was superior to salmeterol in lung function, irrespective of concurrent use of ICS. Dove Medical Press 2007-06 2007-06 /pmc/articles/PMC3321723/ /pubmed/18044688 Text en © 2007 Dove Medical Press Limited. All rights reserved
spellingShingle Original Research
Hodder, Richard
Kesten, Steven
Menjoge, Shailendra
Viel, Klaus
Outcomes in COPD patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroids
title Outcomes in COPD patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroids
title_full Outcomes in COPD patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroids
title_fullStr Outcomes in COPD patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroids
title_full_unstemmed Outcomes in COPD patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroids
title_short Outcomes in COPD patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroids
title_sort outcomes in copd patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroids
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3321723/
https://www.ncbi.nlm.nih.gov/pubmed/18044688
work_keys_str_mv AT hodderrichard outcomesincopdpatientsreceivingtiotropiumorsalmeterolplustreatmentwithinhaledcorticosteroids
AT kestensteven outcomesincopdpatientsreceivingtiotropiumorsalmeterolplustreatmentwithinhaledcorticosteroids
AT menjogeshailendra outcomesincopdpatientsreceivingtiotropiumorsalmeterolplustreatmentwithinhaledcorticosteroids
AT vielklaus outcomesincopdpatientsreceivingtiotropiumorsalmeterolplustreatmentwithinhaledcorticosteroids